ERV2 Stock Overview
Engages in production and co-packing of cannabis-infused beverages in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Molecule Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.02 |
| 52 Week Low | CA$0.0005 |
| Beta | -0.78 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -92.86% |
| 3 Year Change | -99.26% |
| 5 Year Change | n/a |
| Change since IPO | -98.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| ERV2 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | -0.1% |
| 1Y | -92.9% | -16.7% | 7.4% |
Return vs Industry: ERV2 underperformed the German Pharmaceuticals industry which returned -19.5% over the past year.
Return vs Market: ERV2 underperformed the German Market which returned 3.2% over the past year.
Price Volatility
| ERV2 volatility | |
|---|---|
| ERV2 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ERV2 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ERV2's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | David Reingold | molecule.ca |
Molecule Holdings Inc. engages in production and co-packing of cannabis-infused beverages in Canada. It also offers cannabis extracts, beverages, edibles, and topical products directly to provincial retailers. The company offers its beverage products under the PHRESH, KLÕN, EMBODY, and CANAJO brands.
Molecule Holdings Inc. Fundamentals Summary
| ERV2 fundamental statistics | |
|---|---|
| Market cap | €330.75k |
| Earnings (TTM) | -€3.45m |
| Revenue (TTM) | €1.78m |
0.0x
P/S Ratio0.0x
P/E RatioIs ERV2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERV2 income statement (TTM) | |
|---|---|
| Revenue | CA$1.78m |
| Cost of Revenue | CA$2.23m |
| Gross Profit | -CA$449.70k |
| Other Expenses | CA$3.01m |
| Earnings | -CA$3.45m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.035 |
| Gross Margin | -25.27% |
| Net Profit Margin | -194.18% |
| Debt/Equity Ratio | -102.3% |
How did ERV2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/02 03:23 |
| End of Day Share Price | 2024/03/06 00:00 |
| Earnings | 2023/07/31 |
| Annual Earnings | 2022/10/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Molecule Holdings Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|